Maite Martínez

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

José Trigo, Vivek Subbiah, Benjamin Besse et al. · The Lancet Oncology · 2020 · 433 citations

Second-line Treatment, Oncology, Metronomic Therapy +9

Functional systemic <scp>CD</scp> 4 immunity is required for clinical responses to <scp>PD</scp> ‐L1/ <scp>PD</scp> ‐1 blockade therapy

Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal et al. · EMBO Molecular Medicine · 2019 · 211 citations · Full text

Determinants of patient satisfaction with care in a Spanish oncology Day Hospital and its relationship with quality of life

Juan Ignacio Arrarás, José Juan Illarramendi, A. Viúdez et al. · Psycho-Oncology · 2013 · 43 citations

Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

Vivek Subbiah, Luis Paz‐Ares, Benjamin Besse et al. · Lung Cancer · 2020 · 35 citations · Full text

The EORTC information questionnaire, EORTC QLQ-INFO25. Validation study for Spanish patients

Juan Ignacio Arrarás, Ana Manterola, Berta Hernández et al. · Clinical & Translational Oncology · 2011 · 27 citations

Eortc Qlq-info25, Health Policy, Patient Safety +8